Federico Bernal

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College, Aileron Therapeutics, Inc.. Active years: 2014-2020.

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 87(Granted Patents)

Location History:

Brookline, MA (US) (2014 - 2019)
Gaithersburg, MD (US) (2017 - 2020)

Company Filing History:

3 out of 1,265

Dana-Farber-Cancer Institute Inc.

Aileron Therapeutics, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 2014-2020

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10822374 - Cancer therapies and diagnostics (2020-11-03),

2. 10202431 - Stabilized P53 peptides and uses thereof (2019-02-12),

3. 9783586 - Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods (2017-10-10),

4. 9527896 - Stabilized p53 peptides and uses thereof (2016-12-27),

5. 8889632 - Stabilized p53 peptides and uses thereof (2014-11-18),

Title: Innovations in Cancer Therapies by Federico Bernal

Introduction

Federico Bernal is a prominent inventor based in Brookline, MA (US), known for his significant contributions to cancer therapies and diagnostics. With a total of 5 patents, Bernal has focused on enhancing the understanding and treatment of cancer through innovative methods.

Latest Patents

Bernal's latest patents include groundbreaking work on cancer therapies and diagnostics. One notable patent is for compositions and methods aimed at increasing p53-dependent transcriptional activity in a cell. Another significant invention involves stabilized p53 peptides, which are cross-linked peptides related to human p53. These peptides bind to HMD2 or a family member of HMD2, promoting apoptosis and aiding in the treatment and identification of therapeutic agents that interact with HMD2.

Career Highlights

Throughout his career, Bernal has worked with esteemed institutions such as the Dana-Farber Cancer Institute and Harvard College. His work in these prestigious organizations has allowed him to advance his research and contribute to the field of cancer treatment significantly.

Collaborations

Bernal has collaborated with notable colleagues, including Loren D. Walensky and Gregory Lawrence Verdine. These partnerships have further enriched his research and innovations in cancer therapies.

Conclusion

Federico Bernal's work exemplifies the impact of innovative thinking in the field of cancer research. His patents and collaborations highlight his commitment to improving cancer therapies and diagnostics, making a lasting contribution to medical science.